Sentiment-Signal
9,4
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Stammdaten
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.
Unternehmen & Branche
| Name | Cullinan Therapeutics, Inc. |
|---|---|
| Ticker | CGEM |
| CIK | 0001789972 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Medical - Pharmaceuticals |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 782,0 Mio. USD |
| Beta | -0,11 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -219,879,000 | 448,374,000 | 408,730,000 | ||
| 2025-09-30 | 10-Q | -50,610,000 | 484,126,000 | 451,369,000 | ||
| 2025-06-30 | 10-Q | -70,055,000 | 520,329,000 | 492,146,000 | ||
| 2025-03-31 | 10-Q | -48,501,000 | 579,681,000 | 551,839,000 | ||
| 2024-12-31 | 10-K | -167,383,000 | 621,824,000 | 590,328,000 | ||
| 2024-09-30 | 10-Q | -40,560,000 | -0.69 | 653,254,000 | 627,862,000 | |
| 2024-06-30 | 10-Q | -42,028,000 | -0.75 | 681,216,000 | 656,221,000 | |
| 2024-03-31 | 10-Q | -37,148,000 | -0.86 | 449,430,000 | 425,665,000 | |
| 2023-12-31 | 10-K | -153,162,000 | -3.69 | 484,182,000 | 453,703,000 | |
| 2023-09-30 | 10-Q | -39,183,000 | -0.91 | 494,707,000 | 468,817,000 | |
| 2023-06-30 | 10-Q | -32,214,000 | -0.82 | 521,984,000 | 499,574,000 | |
| 2023-03-31 | 10-Q | -57,962,000 | -1.42 | 514,990,000 | 485,649,000 | |
| 2022-12-31 | 10-K | 0 | 111,214,000 | 2.38 | 561,117,000 | 535,029,000 |
| 2022-09-30 | 10-Q | 0 | -24,804,000 | -0.54 | 617,237,000 | 586,128,000 |
| 2022-06-30 | 10-Q | 0 | 174,898,000 | 3.77 | 667,249,000 | 604,538,000 |
| 2022-03-31 | 10-Q | 0 | -12,098,000 | -0.27 | 437,463,000 | 418,702,000 |
| 2021-12-31 | 10-K | 18,943,000 | -65,570,000 | -1.52 | 437,185,000 | 424,971,000 |
| 2021-09-30 | 10-Q | 0 | -17,350,000 | -0.40 | 453,404,000 | 443,386,000 |
| 2021-06-30 | 10-Q | 0 | -15,636,000 | -0.36 | 464,353,000 | 455,549,000 |
| 2021-03-31 | 10-Q | 18,943,000 | -70,000 | 479,666,000 | 466,901,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-02-20 | Fenton Mary Kay | Officer, Chief Financial Officer | Open Market Sale | -4,398 | 13.62 | -59,900.76 | -4,0% | |
| 2025-10-28 | Lynx1 Capital Management LP | 10% Owner | Open Market Purchase | 165,667 | 8.40 | 1,391,685.63 | +93,6% | |
| 2025-10-17 | Lynx1 Capital Management LP | 10% Owner | Open Market Purchase | 32,217 | 7.84 | 252,565.17 | +17,0% | |
| 2025-10-16 | Lynx1 Capital Management LP | 10% Owner | Open Market Purchase | 150,000 | 8.86 | 1,328,250.00 | +89,3% | |
| 2025-10-15 | Lynx1 Capital Management LP | 10% Owner | Open Market Purchase | 51,500 | 7.94 | 409,049.05 | +27,5% | |
| 2025-10-14 | Lynx1 Capital Management LP | 10% Owner | Open Market Purchase | 15,032 | 7.59 | 114,047.78 | +7,7% | |
| 2025-10-10 | Lynx1 Capital Management LP | 10% Owner | Open Market Purchase | 277,298 | 7.36 | 2,041,384.69 | +137,3% | |
| 2025-10-09 | Lynx1 Capital Management LP | 10% Owner | Open Market Purchase | 626,043 | 6.70 | 4,191,858.72 | +281,9% | |
| 2025-10-08 | Lynx1 Capital Management LP | 10% Owner | Open Market Purchase | 556,300 | 6.46 | 3,593,698.00 | +241,7% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.